Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Cytomegalovirus Infection - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Cytomegalovirus Infection - Pipeline Insight, 2024" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Cytomegalovirus Infection- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus Infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus Infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus Infection commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus Infection.
Cytomegalovirus Infection Emerging Drugs Chapters
This segment of the Cytomegalovirus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cytomegalovirus Infection Emerging Drugs
mRNA-1647: Moderna
mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into a majority of cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB has the potential to prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of CMV.
SPYVLP01: SpyBiotech
SPYVLP01 is a candidate vaccine developed by SpyBiotech targeting human cytomegalovirus (HCMV) through its innovative Hepatitis B virus-like-particle platform technology. This vaccine aims to stimulate the immune system to produce antibodies against HCMV, a virus that can cause significant morbidity, including congenital abnormalities like low birth weight, hearing loss, visual impairment, and microcephaly. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CMV.
TRL345: Trellis Bioscience
TRL345 is a high-affinity, native human antibody that targets the most conserved site on the glycoprotein B (gB) of human cytomegalovirus (HCMV). This antibody plays a crucial role in neutralizing HCMV infection by binding to the gB protein, which is associated with the virus's entry into human cells. The exceptional affinity and specificity of TRL345 make it a promising candidate for combating HCMV infection, particularly in scenarios like congenital transmission where high-affinity antibodies are essential for effective protection. Currently, the drug is in Phase I stage of its clinical trial for the treatment of cytomegalovirus infection.
Cytomegalovirus Infection: Therapeutic Assessment
This segment of the report provides insights about the different Cytomegalovirus Infection drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cytomegalovirus Infection
There are approx. 15+ key companies which are developing the therapies for Cytomegalovirus Infection. The companies which have their Cytomegalovirus Infection drug candidates in the most advanced stage, i.e. Phase III include, Moderna.
Key Questions
- How many companies are developing Cytomegalovirus Infection drugs?
- How many Cytomegalovirus Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus Infection?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus Infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cytomegalovirus Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Vir Biotechnology
- SpyBiotech Limited
- Moderna
- VBI Vaccines
- Trellis Bioscience
- GlaxoSmithKline
- AlloVir
Key Products
- VIR-1388
- SPYVAC01
- mRNA-1647
- VBI-1501
- TRL 345
- GSK 3993129A
- Posoleucel
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Cytomegalovirus Infection Report Insights
- Cytomegalovirus Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cytomegalovirus Infection Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/unnw5q
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
